XSHE
300485
Market cap603mUSD
Oct 09, Last price
8.57CNY
1D
2.27%
1Q
-11.92%
Jan 2017
-59.98%
IPO
-43.73%
Name
Beijing Science Sun Pharmaceutical Co Ltd
Chart & performance
P/E
283.29
P/S
10.20
EPS
0.03
Div yield, %
0.26%
Shrs. gr., 5y
0.28%
Rev. gr., 5y
-17.37%
Revenues
405m
-2.82%
Net income
15m
P
CFO
27m
-80.09%
Dividend
May 27, 20260.03 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Beijing Science Sun Pharmaceutical Co., Ltd. is a company, established in 1999 and headquartered in Beijing, China, that operates within the Chinese pharmaceutical market. It is dedicated to the research, development, manufacturing, and distribution of injectable medications. The firm offers a wide array of products designed to treat conditions related to the cardiovascular, cerebrovascular, immunomodulatory, and nervous systems, among other health areas.
Key people
Dongna Liang
Chief Financial Officer · since 2024
Yinfu Shen
Chief Marketing Officer
Biao Ma
Chairman of the Board, General Manager · since 2001
Shuangquan Kong
Chief Engineer
Li Ma
Deputy General Manager, Director · since 2024
Xuefeng Wang
Deputy General Manager, Secretary of the Board, Director · since 2011
Wentao Xu
Director
Changcheng Yin
Director
Yunping Dai
Independent Director · since 2024
Feng Liu
Independent Director · since 2024
Yanheng Song
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||